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Abstract
Background: Posterior reversible encephalopathy syndrome (PRES) is an uncommon pathology characterized by
the acute onset of headache, vomiting, altered consciousness, seizures and focal neurological deficits. It was initially
described in the setting of hypertension, uremia and immunosuppression. In the last decade there have been
emerging reports of PRES in patients with advanced human immunodeficiency virus (HIV)-infection in the presence
of hypertension, dialysis, hypercalcaemia and two opportunistic infections: blastomycosis and tuberculosis (TB).
Case presentation: Here we present the case of a 54 year old male being treated for disseminated varicella zoster
virus (VZV) and vasculopathy in the setting of HIV infection who acutely deteriorated to the point of requiring
intubation. His clinicoradiological diagnosis was of PRES and he subsequently improved within 72 h with supportive
management. Serial neuroimaging correlated with the clinical findings. The pathogenesis of PRES is poorly
understood but is thought to stem from vasogenic oedema either as a result of loss of endothelial integrity and
transudate of fluid across the blood–brain barrier, or secondary to vasospasm resulting in tissue oedema in the
absence of infarction. How HIV infection impacts on this model is unclear. It is possible the HIV infection causes
endothelial dysfunction and disruption of the blood–brain barrier that may be further exacerbated by infections in
the central nervous system.
Conclusion: The phenomenon of PRES in advanced HIV is an important clinical entity for both physicians and
critical care doctors to recognize firstly given its potential mortality but also because of its favourable prognosis and
reversibility with supportive care and treatment of underlying causes.
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Background
PRES is a clinicoradiological entity characterized by the
development of headache, hypertension, altered menta-
tion, focal neurological deficits and seizures and by the
MRI findings of symmetric and bilateral subcortical
oedema including mainly the parietal and occipital lobes.
Importantly the changes are transient and reversible.
PRES was originally described in association with hyper-
tension, uremia and immunosuppression [1]. The patho-
genesis of PRES is poorly understood but is thought to
involve vasogenic dysregulation and/or disruption of
the blood–brain barrier. Current hypotheses include se-
vere hypertension causing a failure of autoregulation
with endothelial injury leading to vasogenic oedema.
The alternate hypothesis is of vasoconstriction and
hypoperfusion leading to brain ischemia and subse-
quent oedema in the absence of infarction. The typical
anatomy of PRES, in the posterior regions, is thought
to reflect poorer sympathetic innervation as compared
to the anterior circulation.
There have been emerging reports that several patho-
genic processes can lead to PRES in HIV-infected adults.
In nine previously published cases, four were associated
with hypertension [2,3], including two with end-stage
kidney disease requiring dialysis [4,5], one with hypercal-
cemia [6], and two with disseminated infections (blasto-
mycosis [7] and TB [8]). In one report no precipitating
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factor could be found [9]. While hypertension and
endothelial damage/dysfunction appear to be two main
factors contributing to PRES, HIV infection is also
known to be associated with vascular changes, altered
vascular reactivity and focal blood–brain barrier dis-
ruption [10]. Here we report the development of PRES
in a patient with disseminated VZV with vasculopathy
and advanced HIV infection that was severe enough to
warrant intubation.
Case presentation
A 54 year old male presented to another hospital with
a three day history of headache, vomiting, diplopia
and photophobia. His past medical history included
advanced HIV infection (recent CD4 T-cell count 173
cells/μL and HIV Viral load 36 copies/mL), anal squa-
mous cell carcinoma (SCC) treated with chemo- and
radiotherapy and known single metastasis to the liver,
and back pain. Medications at admission were: darunavir
600 mg PO BD, ritonavir 100 mg PO BD, etravirine
200 mg PO BD, raltegravir 400 mg PO BD esomeprazole
20 mg PO daily, paracetamol 1 g PO QID and oxycontin
20 mg PO BD. The patient lived independently and had
a 40 pack-year history of smoking. On examination
he was febrile to 38.2°C. All other vital signs were within
normal limits. Cardiopulmonary and abdominal exams
were normal. Neurologically he had an expressive dys-
phasia, a left sixth nerve palsy and mild global ataxia.
Computer-tomography (CT) imaging of the brain was
within normal limits. The patient underwent a lumbar
puncture that showed 101×106 leukocytes (95% mono-
nuclear cells and 5% polymorphs), 20×106 erythrocytes,
elevated protein 3.44 g/L, and normal glucose 3.8 mmol/L.
He was admitted with presumed meningitis and treated
with ceftriaxone 2 g IV BD, benzyl penicillin 2.4 g IV q4h,
dexamethasone 10 mg PO QID. Later on Day 0 he under-
went a magnetic resonance imaging (MRI) scan of the brain
that showed multiple non-enhancing lesions demonstrated
on the T2 weighted sequences that were not associated
with vasogenic oedema. These were considered most con-
sistent with an infective cause and were not typical of meta-
static disease. The patient was commenced on clindamycin
600 mg IV QID and pyrimethanine 25 mg/folinic acid for
empirical treatment of toxoplasmosis. On Day 1 the patient
developed a vesicular rash over his face, trunk and back. A
vesicle was de-roofed and swabbed and the patient was
commenced on aciclovir 700 mg IV TDS for presumed dis-
seminated VZV prior to transfer to our centre.
Upon arrival at our unit ceftriaxone and benzyl peni-
cillin were ceased given the lack of supporting evidence
for bacterial meningitis and dexamethasone reduced to
4 mg PO BD. A repeat MRI with T2 weighted FLAIR
sequence showed nodularly enhancing lesions in the
right cerebellum, right cerebellopontine angle and right
anterior temporal cortex at the grey-white matter junc-
tion and a subcortical U-fibre high signal intensity lesion
in the right frontoparietal area reported as possibly
representing progressive multifocal leukoencephalopathy
(PML) (Figure 1ai) and ii)). The swab from the vesicular
rash was positive for VZV and our provisional diagnosis
was disseminated VZV with associated cerebral vasculopathy.
We planned for ten days of IV aciclovir with follow-up
MRI and brain biopsy if the lesions had not resolved.
Differential diagnoses included Toxoplasma, lymphoma
and PML. Subsequently PCR detected VZV and
Epstein-Barr virus (EBV) in the CSF but testing for
Cryptococcal antigen and JC virus were negative.
On Day 10 the patient complained of severe bilateral
headache. He was afebrile with a blood pressure (BP) of
165/62. There were no new focal neurological deficits
and he was treated with 10 mg PO oxycodone. Three
hours later he suffered an unwitnessed fall. BP at this
time was 170/96. An additional three hours later he had
a witnessed generalized tonic-clonic seizure (GTCS) as-
sociated with tongue biting and loss of urinary and fecal
continence. His BP was 170/90. He received diazepam
20 mg IV and was loaded with phenytoin 1 g IV. Eight
hours following this he had a second witnessed GTCS
associated with fever to 39.3°C. His oxygen saturation
was 98% on room air and BP was 131/82. On review he
would not open his eyes, made no sounds and extended
to painful stimuli with global hyper-reflexia and a left
Babinski sign. The patient underwent immediate ICU re-
view for airway management to facilitate an urgent CT
Brain. The CT showed hypoattenuating areas in the right
frontal lobe and bilateral occipital lobes suggesting acute
PRES. A subsequent MRI with T2 weighted FLAIR se-
quence was also consistent with PRES (Figure 1bi-ii).
The patient was taken to ICU for intubation. His
phenytoin was switched to levetiracetam 500 mg IV
BD due to deranged liver function tests. The consultant
neurologist made a provisional diagnosis of PRES
secondary to progressive VZV vasculopathy. Serum
creatinine (91 μmol/L; eGFR 75) and calcium levels
(2.44 mmol/L) were within normal limits. The differen-
tial diagnoses included immune-reconstitution-inflam-
matory syndrome (IRIS) and PML (although the JC virus
PCR from CSF was negative). The radiological findings
were not consistent with toxoplasmosis. An electro-
encephalogram did not show epileptiform activity. Three
days after intubation the patient was hypertensive to
172/88 with a mean arterial pressure (MAP) consistently
over 100 (in the 3 days prior his MAP was stable at 80).
He was treated with IV hydralazine PRN before being
commenced on amlodipine 10 mg via a nasogastic (NG)
tube and captopril 25 mg NG TDS. His antiretroviral
therapy (ART) treatment was withheld for three days
due to the incompatibility of some drugs with NG
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administration. Two days after intubation the patient’s sed-
ation was weaned and he was able to follow commands. He
was extubated three days after intubation at which time his
eyes opened spontaneously, he was speaking spontaneously
and obeying commands, and was returned to the ward. A
follow-up MRI showed resolution of vasogenic oedema on
T2 weighted FLAIR sequence (Figure 1ci-ii). A CT angio-




Figure 1 Sequential T2- weighted FLAIR MRI Brain imaging. a) Nodularly enhancing lesions on initial presentation in the i) right anterior
temporal cortex and ii) right cerebellum. Subcortical U-fibre high signal intensity lesion in the right frontoparietal area as shown by T2- weighted
FLAIR MRI. b) Marked interval increase in the signal hyperintensities demonstrated by T2- weighted FLAIR MRI in i) frontal, parietal and temporal
lobes and the ii) cortical and subcortical/deep white matter of the occipital lobes following acute deterioration and consistent with PRES.
c) Interval reduction of signal hyperintensities as shown by T2- weighted FLAIR MRI in i) parietal and ii) occipital lobes demonstrating resolving
vasogenic oedema.
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The patient completed 14 days of IV aciclovir, his dexa-
methasone was weaned and ceased and clindamycin,
pyrimethanine, folinic acid and captopril ceased. After a
week in an inpatient rehabilitation unit he was discharged
home with a persistent left sixth nerve palsy.
Conclusions
To our knowledge this is the first report of PRES in
an HIV-infected patient in the setting of disseminated
VZV and associated vasculopathy. Additionally it is the
first reported case of HIV-associated PRES severe
enough to warrant intubation. Here, the presentation of
a patient with fevers, headache and visual disturbance
and subsequent findings of MRI lesions at the grey-
white matter junction, CSF containing a mixed mono-
nuclear leukocytosis and erythrocytosis and VZV IgG
are all consistent with the diagnosis of VZV vasculopathy
[11]. This condition results from productive viral infec-
tion of cerebral arteries and has a range of known se-
quelae including aneurysm, cerebral and subarachnoid
hemmorrhage, arterial ectasia and carotid artery dissec-
tion [11]. VZV vasculopathy is generally treated with
IV acyclovir with or without concomitant steroids. It is
thought that steroids may reduce associated inflamma-
tion, however this should be weighed against the risk
of promoting viral infection [11]. Overall the evidence
for steroid use in this condition remains unclear [12].
To our knowledge this is the first report of VZV
vasculopathy associated with PRES, and it is likely this
syndrome is part of the ever-widening spectrum of
VZV-associated vascular disease.
In previously published cases of HIV-associated PRES,
all had similarly advanced immunodeficiency with seven of
nine patients having CD4 counts <200 cells/μL [2-8] while
the remaining were <300 cells/μL [3,9]. Interestingly, here
the patient had no history of hypertension and throughout
the first 11 days of admission his BP had a baseline of
140/90. The highest recorded BP was 172/88 triggering
treatment. Possible risk factors contributing to endothelial
damage in this patient include: undiagnosed hypertension,
smoking, HIV infection [13] and the use of protease inhi-
bitors [14]. This case is similar to that reported by Saeed
et al. [7] of an HIV-infected patient with no previous
hypertension presenting with a disseminated infection and
developing concurrent hypertension during admission.
Although rare, PRES is important to recognize in
order to reduce associated morbidity and mortality. It is
now becoming apparent that patients with advanced
HIV infection and CD4 counts <300 cells/μL may be at
risk of developing PRES either in isolation or in the set-
ting of hypertension, hypercalcemia or disseminated op-
portunistic infection, particularly those penetrating the
CNS. Fortunately prognosis with supportive care and re-
versal of underlying causes is good.
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